Monte Rosa Therapeutics, Inc. GLUE Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s change in accrued liabilities?
- Monte Rosa Therapeutics, Inc. (GLUE) reported change in accrued liabilities of -$3.71M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s change in accrued liabilities decreased by 42.4% year-over-year, from -$2.61M to -$3.71M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s change in accrued liabilities?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s change in accrued liabilities has grown at a 5.3% compound annual growth rate (CAGR), from $6.73M to $7.85M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.